AstraZeneca established its drug development research division in Hong Kong and collaborate with the Humanity and Health Clinical Trial Centre (HKSAR) with the invaluable support of the HKSAR Government!
The Humanity & Health Clinical Trial Centre Team joined the kick-off event on 23-24 Nov at Science Park!
Our Chairman, Prof. George Lau being invited to join the Expert Panel Discussion session of "Clinical Trial Start-Up"!
The Event Guests were invited by Humanity & Health Clinical Trial Centre to participate in a site visit and engage with site experts based on their individual requirements.
-
Services
Focus on conducting Phase II, III & IV clinical trials
Provide one-stop service with qualified Principal Investigator,
Experienced research staff & advanced facilities,
Good compliance with GCP & protocol
Patient centered service
High efficiency with fast start-up, high recruitment & retention rate and low screen failure rate
-
Facilities
Locked cabinets & 2-8°C refrigerators for drug storage,
Biological specimen storage area -20°C and -80°C Freezers
Biological Safety Cabinet for drug preparation
Refrigerated centrifuge for sample processing
ECG, Ultrasound, Echo, Holter Monitoring
Endoscopy, IV Infusions system
Imaging scans: X-ray, CT, MRI, PET
-
News & Events
Our co-organized event with Hong Kong Chinese Medical Association (1st Feb 2024) Details
Humanity & Health Clinical Trial Centre becomes the Strategic Partner of AstraZeneca! Details
Recruiting studies:
Newly diagnosed unresectable/metastatic gastric, GEJ and esophageal adenocarcinoma
Non-Small-Cell Lung Cancer (with no EGFR or ALK genomic tumor aberrations) - Immunotherapy (Treatment naïve)
Gastrointestinal stroma tumors - Treatment experienced with Imatinib
Nonalcoholic Steatohepatitis - pre-diabetes or diabetes, stage 2/3 fibrosis
Our Achievements
“Our average retention rate is >90%”
“Average study start-up period is less than 3 months”
-
Randomized 8 patients in 6 months! Top 3 global recruitment site.
An advanced ALK positive NSCLC study
-
Randomized 4 patients, 0% screen failure rate.
A study of advanced HCC with no previous systemic anticancer therapy and a primary biliary cirrhosis study.
-
Randomized 41 patients in total, in which 30 is achieved in 6 months. Top 3 global recruitment site.
A study of unsesectable HCC.
